3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Specimen Handling
49
Letrozole
42
Fulvestrant
42
Paclitaxel
38
pembrolizumab
34
Magnetic Resonance Spectroscopy
31
Carboplatin
31
ribociclib
26
Trastuzumab
26
Biopsy
26
exemestane
23
Anastrozole
23
Capecitabine
22
palbociclib
21
pertuzumab
20
Tamoxifen
19
trastuzumab deruxtecan
18
abemaciclib
18
Cyclophosphamide
17
Taxes
15
Radiotherapy
14
130-nm albumin-bound paclitaxel
12
elacestrant
11
Docetaxel
11
sacituzumab govitecan
9
olaparib
9
Standard of Care
9
Radiation
9
Goserelin
9
Gemcitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
RAD1901
×
Breast
×
30 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled